Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy

被引：23

作者：

Wang, Shupeng ^{[1
]}

Jin, Shaohua ^{[1
]}

Shu, Qinghai ^{[1
]}

Wu, Song ^{[2
]}

机构：

[1] Beijing Inst Technol, Sch Mat Sci & Engn, Beijing 100081, Peoples R China

[2] Shenzhen Univ, Sch Med, Shenzhen 518000, Peoples R China

来源：

PHARMACEUTICS | 2021年 / 13卷 / 02期

基金：

中国国家自然科学基金;

关键词：

intravesical treatment; drug instillation; bladder cancer; bladder penetrating barriers; urothelium; bladder mucosa;

D O I：

10.3390/pharmaceutics13020166

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Bladder cancer is a significant public health concern and social burden due to its high recurrence risk. Intravesical drug instillation is the primary therapy for bladder cancer to prevent recurrence. However, the intravesical drug therapeutic effect is limited by bladder penetrating barriers. The inadequate intravesical treatment might cause the low drug concentration in lesions, resulting in a high recurrence/progression rate of bladder cancer. Many strategies to get drugs across bladder penetrating barriers have been developed to improve intravesical treatment, including physical and chemical methods. This review summarizes the classical and updated literature and presents insights into great therapeutic potential strategies to overcome bladder penetrating barriers for improving the intravesical treatment of bladder cancer.

引用

页码：1 / 14

页数：14

共 122 条

[1] Cell-cell junctions: structure and regulation in physiology and pathology [J].

Adil, Mir S. ;

Narayanan, S. Priya ;

Somanath, Payaningal R. .

TISSUE BARRIERS, 2021, 9 (01)

[2] The use of intravesical BCG in urothelial carcinoma of the bladder [J].

Alhunaidi, Omar ;

Zlotta, Alexandre R. .

ECANCERMEDICALSCIENCE, 2019, 13

[3] A review on chitosan and its nanocomposites in drug delivery [J].

Ali, Akbar ;

Ahmed, Shakeel .

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 109 :273-286

[4] Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer [J].

Arends, Tom J. H. ;

Nativ, Ofer ;

Maffezzini, Massimo ;

de Cobelli, Ottavio ;

Canepa, Giorgio ;

Verweij, Fabrizio ;

Moskovitz, Boaz ;

van der Heijden, Antoine G. ;

Witjes, J. Alfred .

EUROPEAN UROLOGY, 2016, 69 (06) :1046-1052

[5] Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial [J].

Au, JLS ;

Badalament, RA ;

Wientjes, MG ;

Young, DC ;

Warner, JA ;

Venema, PL ;

Pollifrone, DL ;

Harbrecht, JD ;

Chin, JL ;

Lerner, SP ;

Miles, BJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (08) :597-604

[6] ENHANCEMENT OF BACILLUS CALMETTE-GUERIN ATTACHMENT TO THE UROTHELIUM BY REMOVAL OF THE RABBIT BLADDER MUCIN LAYER [J].

BADALAMENT, RA ;

FRANKLIN, GL ;

PAGE, CM ;

DASANI, BM ;

WIENTJES, MG ;

DRAGO, JR .

JOURNAL OF UROLOGY, 1992, 147 (02) :482-485

[7] Is extracorporeal shock wave lithotripsy a current treatment for urolithiasis? A systematic review [J].

Bahilo Mateu, P. ;

Budia Alba, A. ;

Liatsikos, E. ;

Trassierra Villa, M. ;

Lopez-Acon, J. D. ;

de Guzman Ordaz, D. ;

Boronat Tormo, F. .

ACTAS UROLOGICAS ESPANOLAS, 2017, 41 (07) :426-434

[8] Tumor Cell Dissociation Removes Malignant Bladder Tumors [J].

Bao, Qunqun ;

Hu, Ping ;

Ren, Weiwei ;

Guo, Yuedong ;

Shi, Jianlin .

CHEM, 2020, 6 (09) :2283-2299

[9] Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model [J].

Berndt-Paetz, Mandy ;

Schulze, Philipp ;

Stenglein, Philipp C. ;

Weimann, Annett ;

Wang, Qiang ;

Horn, Lars-Christian ;

Riyad, Yasser M. ;

Griebel, Jan ;

Hermann, Ralf ;

Glasows, Annegret ;

Stolzenburg, Jens-Uwe ;

Neuhaus, Jochen .

MOLECULAR CANCER THERAPEUTICS, 2019, 18 (04) :743-750

[10] Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial [J].

Boorjian, Stephen A. ;

Alemozaffar, Mehrdad ;

Konety, Badrinath R. ;

Shore, Neal D. ;

Gomella, Leonard G. ;

Kamat, Ashish M. ;

Bivalacqua, Trinity J. ;

Montgomery, Jeffrey S. ;

Lerner, Seth P. ;

Busby, Joseph E. ;

Poch, Michael ;

Crispen, Paul L. ;

Steinberg, Gary D. ;

Schuckman, Anne K. ;

Downs, Tracy M. ;

Svatek, Robert S. ;

Mashni, Joseph, Jr. ;

Lane, Brian R. ;

Guzzo, Thomas J. ;

Bratslavsky, Gennady ;

Karsh, Lawrence I. ;

Woods, Michael E. ;

Brown, Gordon ;

Canter, Daniel ;

Luchey, Adam ;

Lotan, Yair ;

Krupski, Tracey ;

Inman, Brant A. ;

Williams, Michael B. ;

Cookson, Michael S. ;

Keegan, Kirk A. ;

Andriole, Gerald L., Jr. ;

Sankin, Alexander I. ;

Boyd, Alan ;

O'Donnell, Michael A. ;

Sawutz, David ;

Philipson, Richard ;

Coll, Ruth ;

Narayan, Vikram M. ;

Treasure, F. Peter ;

Yla-Herttuala, Seppo ;

Parker, Nigel R. ;

Dinney, Colin P. N. .

LANCET ONCOLOGY, 2021, 22 (01) :107-117

← 1 2 3 4 5 6 7 8 9 10 →